Crizotinib

Crizotinib Reactions 1680, p100 - 2 Dec 2017 ALK G1269A mutation leading to crizotinib resistance: case report In a retrospective study of 8 patients, a 29-year-old man developed drug resistance due to ALK G1269A mutation during treatment with crizotinib [route, dosages not stated]. He had a diagnosis of stage IV non-small-cell lung cancer (NSCLC) and he received anaplastic lymphoma kinase (ALK) inhibitor therapy. Initially, he received crizotinib therapy, which was followed by ceritinib therapy. During the crizotinib therapy, he developed ALK G1269A mutation, which led to the resistance of ALK inhibitor therapy [duration of treatment to reaction onset not stated]. On the ceritinib therapy, he had a remission of only 3 months. After this, his disease progressed with the pleural effusion and mediastinal lymph nodes development [reaction outcome not stated]. Author comment: "One patient, who experienced PD during alectinib treatment, had ALK G1269A mutation (patient 4). The G1269A mutation is reported to confer resistance to crizotinib while conferring sensitivity to alectinib and ceritinib; in this case, treatment with crizotinib before ceritinib treatment might affect G1269A mutation expression." Oya Y, et al. Clinical efficacy of alectinib in patients with ALK-rearranged non- small cell lung cancer after ceritinib failure. Anticancer Research 37: 6477-6480, No. 11, Nov 2017. Available from: URL: http://doi.org/10.21873/anticanres.12103 - Japan 803284654 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680 http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Reactions Weekly Springer Journals

Crizotinib

Reactions Weekly , Volume 1680 (1) – Dec 2, 2017
Free
1 page
Loading next page...
1 Page
 
/lp/springer_journal/crizotinib-NGy1KdPK8H
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG, part of Springer Nature
Subject
Medicine & Public Health; Drug Safety and Pharmacovigilance; Pharmacology/Toxicology
ISSN
0114-9954
eISSN
1179-2051
D.O.I.
10.1007/s40278-017-39031-8
Publisher site
See Article on Publisher Site

Abstract

Reactions 1680, p100 - 2 Dec 2017 ALK G1269A mutation leading to crizotinib resistance: case report In a retrospective study of 8 patients, a 29-year-old man developed drug resistance due to ALK G1269A mutation during treatment with crizotinib [route, dosages not stated]. He had a diagnosis of stage IV non-small-cell lung cancer (NSCLC) and he received anaplastic lymphoma kinase (ALK) inhibitor therapy. Initially, he received crizotinib therapy, which was followed by ceritinib therapy. During the crizotinib therapy, he developed ALK G1269A mutation, which led to the resistance of ALK inhibitor therapy [duration of treatment to reaction onset not stated]. On the ceritinib therapy, he had a remission of only 3 months. After this, his disease progressed with the pleural effusion and mediastinal lymph nodes development [reaction outcome not stated]. Author comment: "One patient, who experienced PD during alectinib treatment, had ALK G1269A mutation (patient 4). The G1269A mutation is reported to confer resistance to crizotinib while conferring sensitivity to alectinib and ceritinib; in this case, treatment with crizotinib before ceritinib treatment might affect G1269A mutation expression." Oya Y, et al. Clinical efficacy of alectinib in patients with ALK-rearranged non- small cell lung cancer after ceritinib failure. Anticancer Research 37: 6477-6480, No. 11, Nov 2017. Available from: URL: http://doi.org/10.21873/anticanres.12103 - Japan 803284654 0114-9954/17/1680-0001/$14.95 Adis © 2017 Springer International Publishing AG. All rights reserved Reactions 2 Dec 2017 No. 1680

Journal

Reactions WeeklySpringer Journals

Published: Dec 2, 2017

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off